tadalafil

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Pulmonary Arterial Hypertension

Conditions

Pulmonary Arterial Hypertension

Trial Timeline

Jan 1, 2010 → Aug 1, 2014

NCT ID

NCT01066845

About tadalafil

tadalafil is a pre-clinical stage product being developed by Eli Lilly for Pulmonary Arterial Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT01066845. Target conditions include Pulmonary Arterial Hypertension.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (13)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02252367	Approved	Completed	Dec 1, 2015	Jun 1, 2020	Prostatic Hyperplasia
NCT02224846	Approved	Completed	Oct 1, 2014	May 1, 2017	Erectile Dysfunction
NCT01326117	Approved	Withdrawn	Apr 1, 2011	Dec 1, 2013	Gastroparesis
NCT01324999	Phase 2/3	Completed	Mar 1, 2011	Oct 1, 2013	Pulmonary Hypertension
NCT01183650	Phase 1	Completed	Jul 1, 2010	Apr 1, 2011	Benign Prostatic Hyperplasia
NCT01066845	Pre-clinical	Completed	Jan 1, 2010	Aug 1, 2014	Pulmonary Arterial Hypertension
NCT00822354	Pre-clinical	Completed	Sep 1, 2008	Apr 1, 2010	Raynaud
NCT00157326	Phase 2	Completed	Sep 1, 2005	Jun 1, 2006	Hypertension
NCT00333281	Approved	Completed	Jun 1, 2005	Aug 1, 2006	Erectile Dysfunction
NCT00422578	Approved	Completed	Oct 1, 2004	Sep 1, 2005	Impotence
NCT00421083	Phase 3	Completed	Sep 1, 2004	Jun 1, 2005	Erectile Dysfunction
NCT00547417	Phase 3	Completed	Jul 1, 2003	Mar 1, 2004	Impotence
NCT00547599	Approved	Completed	Apr 1, 2003	Jan 1, 2004	Impotence

Competing Products

20 competing products in Pulmonary Arterial Hypertension

See all competitors

Product	Company	Stage	Hype Score
AP01	Avalyn Pharmaceuticals	Phase 2	44
macitentan 10 mg	BML, Inc.	Phase 3	76
tadalafil + tadalafil	Eli Lilly	Phase 3	77
CS1 Administration	Cereno Scientific	Phase 2	47
CS1	Cereno Scientific	Pre-clinical	18
TX000045- Dose A + TX000045- Dose B + Placebo	Tectonic Therapeutic	Phase 2	44
Dose A KER-012 + Dose B KER-012 + Dose C KER-012 + Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks	Keros Therapeutics	Phase 2	44
Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) + Placebo	Rein Therapeutics	Phase 1	25
LTI-03 + Placebo	Rein Therapeutics	Phase 1	25
LTI-03 + Placebo	Rein Therapeutics	Phase 2	44
Satralizumab (Genetical Recombination)	Chugai Pharmaceutical	Phase 2	52
DS-1040b + Placebo + Enoxaparin	Daiichi Sankyo	Phase 1/2	41
DS-9231 + Placebo	Daiichi Sankyo	Phase 2	52
Regadenoson	Astellas Pharma	Pre-clinical	23
Reldesemtiv + Placebo	Astellas Pharma	Phase 2	52
Monteplase	Eisai	Approved	85
lysozyme 90 mg + Placebo	Eisai	Approved	85
Prednisolone + Voriconazole	Cipla	Phase 2/3	65
Drotrecogin Alfa (Activated) + Enoxaparin + Placebo + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated)	Eli Lilly	Phase 2	52
tadalafil and ambrisentan upfront combination therapy	Eli Lilly	Approved	85

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved

Olanzapine + PlaceboApproved

exenatide and sitagliptin + exenatide and placeboApproved

Tirzepatide + PlaceboApproved

tadalafilApproved